ARS Pharmaceuticals Inc (SPRY) Q4 2025 Earnings Call Transcript

Why It Matters

The results demonstrate ARS’s ability to capture share and expand the overall epinephrine market, positioning Neffy for sustained revenue growth and global scale while maintaining a strong, non‑dilutive balance sheet.

Key Takeaways

• Neffy Q3 revenue $31.3M, 2.5x QoQ growth.
• Market share among new prescribers 10.3%, surpassing existing.
• 18,000 providers, 85% increase since August.
• Germany rollout three‑times faster; UK, Japan, China pending.
• $250M term loan, $100M drawn, interest‑only till 2030.

Pulse Analysis

Neffy’s explosive revenue surge reflects a broader shift in the $2 billion U.S. epinephrine market, where needle‑phobic patients increasingly favor auto‑injector alternatives. By capturing 19% of lapsed and 7% of never‑treated patients, ARS is not merely taking share but expanding the addressable pool, a trend reinforced by a 9% year‑over‑year market growth. The company’s direct‑to‑consumer (DTC) initiatives, highlighted by a jump in consumer awareness from 20% to 56%, have amplified demand, while real‑world evidence showing high refill intent underscores durable utilization.

Operationally, ARS’s Get Neffy On Us program removes traditional prescribing friction, offering virtual visits, zero‑co‑pay options, and streamlined prior‑authorization handling. This model mitigates seasonal back‑to‑school slowdowns and improves gross‑to‑net retention as cash prescriptions fell from 20% to 12% of volume. The focus on top‑decile prescribers—who now generate 81% of scripts—combined with a growing pediatrician network and school‑based access, creates a multi‑channel distribution engine that sustains growth beyond peak allergy periods.

Financially, the up‑to‑$250 million term loan, secured at SOFR + 5.5% with interest‑only payments through 2030, provides a low‑cost, non‑dilutive runway that supports both U.S. commercialization and aggressive international expansion. With $288 million in cash, ARS is poised to launch YERNEPI in Germany, the UK, and Japan, and to enter Canada and China by 2026. The Phase 2b urticaria trial, targeting a 2 million‑patient market, adds a high‑potential label extension. Together, these strategic levers position ARS to convert market share gains into profitable, cash‑flow‑positive growth in the coming years.